WuXi XDC, a global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate sector, has announced the mechanical completion of its new manufacturing site in Singapore’s Tuas Biomedical Park. The 25,000 square metre facility will now move into
WuXi XDC Cayman Inc., a global contract research, development, and manufacturing organisation (CRDMO) focused on bioconjugates, has entered into a strategic agreement with AbTis, a South Korea-based biotechnology company specialising in antibody-drug conjugates (ADCs). The Memorandum of Understanding (MOU) aims to
WuXi XDC Cayman Inc., a contract research, development, and manufacturing organisation (CRDMO) specialising in ADCs and bioconjugates, has signed an expanded Memorandum of Understanding (MOU) with LigaChem Biosciences. The agreement broadens their existing collaboration to further accelerate the development of next-generation
WuXi XDC, a contract research, development, and manufacturing organization (CRDMO) based in China, has announced a strategic collaboration with Schreiner MediPharm. This partnership aims to enhance the safety and efficacy of an antibody-drug conjugate (ADC) currently in clinical trials. The
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
